Neurogene Inc [NASDAQ: NGNE] gained 6.69% or 0.72 points to close at $11.49 with a heavy trading volume of 189974 shares.
The daily chart for NGNE points out that the company has recorded -77.01% loss over the past six months.
If we look at the average trading volume of 280.29K shares, NGNE reached to a volume of 189974 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Neurogene Inc [NGNE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NGNE shares is $44.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NGNE stock is a recommendation set at 1.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Neurogene Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 27, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on June 11, 2024, representing the official price target for Neurogene Inc stock. Previously, the target price had yet another raise to $46, while Leerink Partners analysts kept a Outperform rating on NGNE stock.
The Average True Range (ATR) for Neurogene Inc is set at 1.49, with the Price to Sales ratio for NGNE stock in the period of the last 12 months amounting to 176.20. The Price to Book ratio for the last quarter was 0.55, with the Price to Cash per share for the same quarter was set at 21.90.
Trading performance analysis for NGNE stock
Neurogene Inc [NGNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.09. With this latest performance, NGNE shares dropped by -25.49% in over the last four-week period, additionally sinking by -77.01% over the last 6 months – not to mention a drop of -67.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NGNE stock in for the last two-week period is set at 46.39, with the RSI for the last a single of trading hit 51.82, and the three-weeks RSI is set at 43.81 for Neurogene Inc [NGNE]. The present Moving Average for the last 50 days of trading for this stock 15.02, while it was recorded at 11.10 for the last single week of trading, and 29.96 for the last 200 days.
Neurogene Inc [NGNE]: A deeper dive into fundamental analysis
Neurogene Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 20.84 and a Current Ratio set at 20.84.
Neurogene Inc [NGNE]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NGNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Neurogene Inc go to -4.77%.
An analysis of Institutional ownership at Neurogene Inc [NGNE]
There are presently around $113.42%, or 126.92%% of NGNE stock, in the hands of institutional investors. The top three institutional holders of NGNE stocks are: BLACKROCK INC. with ownership of 1.39 million shares, which is approximately 8.2325%. ECOR1 CAPITAL, LLC, holding 1.27 million shares of the stock with an approximate value of $$46.26 million in NGNE stocks shares; and ECOR1 CAPITAL, LLC, currently with $$46.13 million in NGNE stock with ownership which is approximately 7.4833%.
